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A B S T R A C T   
Anthelmintic resistance in equine cyathostomins is both widespread and highly prevalent in the benzimidazole 
and tetrahydropyrimidine classes; however, reports of resistance to macrocyclic lactone (ML) drugs are sparse 
and sporadic. This study reports a case of clear ML resistance in a group of Thoroughbred yearlings imported 
from Ireland to the US in 2019. Fecal egg count reduction (FECR) following ivermectin administered in February 
2020 demonstrated 100% reduction in the US bred yearlings, but 93.5%, 70.5%, and 74.5% reduction in three 
groups of the imported yearlings. The two former groups were then retreated with ivermectin, yielding FECRs of 
33.8% and 23.5%, respectively. Horses from these two groups were then assigned randomly to two possible 
treatments; moxidectin or a triple combination of moxidectin, oxibendazole, and pyrantel pamoate. The groups 
treated with moxidectin had FECRs of 90.2%, 57.3%, and 50.0%, while the triple combination had a 100% FECR 
in all treated groups. Subsequently, the efficacy of ivermectin was reassessed in June 2020 yielding FECRs of 
99.8%, 87.7%, and 62.0% in the three imported groups. The FECRs of the US bred yearlings all remained in the 
99–100% range. This is the first study to clearly demonstrate ML resistance in cyathostomins and to confirm the 
suspicion through reassessment. These data demonstrate that ML-resistant cyathostomins were imported from 
Ireland and serve to illustrate that the global movement of horses has the potential to quickly spread ML-resistant 
parasite isolates around the world. The equine industry is strongly encouraged to routinely monitor anthelmintic 
efficacy, so occurrence of ML resistant cyathostomins can be detected and appropriate interventions imple-
mented as early as possible.   
1. Introduction 
Equine cyathostomin parasites are ubiquitous in grazing horses 
across the world, and anthelmintic resistance is widely documented to 
two of three available drug classes (Kaplan 2002; Peregrine et al., 2014). 
Despite early predictions of resistance developing to macrocyclic lactone 
(ML) anthelmintics (e.g., ivermectin, moxidectin) in cyathostomins 
(Sangster, 1999), to date there have been very few reports published. 
The first report of ML resistance was a conference abstract reporting 
reduced efficacy of moxidectin in donkeys kept at a donkey sanctuary 
(Trawford et al., 2005). However, the donkeys were treated in an 
extra-label manner using oral administration of an injectable formula-
tion registered for ruminants, leading to questions as to the level of 
evidence and the clinical significance to horses. The next report was in a 
herd of Thoroughbred horses in Brazil (Molento et al., 2008), where 
treatment with ivermectin, abamectin and moxidectin all yielded 
reduced efficacies. Since then, a very limited number of studies, all of 
which were multiple-farm surveys, have reported macrocyclic lactone 
resistance in the form of reduced fecal egg count reduction at two weeks 
following administration (Traversa et al., 2009; Milillo et al., 2009; 
Näreaho et al., 2011; Canever et al., 2013; Relf et al., 2014). This is 
remarkable given that ML anthelmintics have been the most widely 
administered drugs in horses by far over the past several decades 
(Stratford et al., 2014; Becher et al., 2018). It is also noteworthy that the 
reports published, thus far, are from Europe (4) and Brazil (1), but so far 
none have been published from North America, despite a remarkably 
high anthelmintic treatment intensity, especially in the Thoroughbred 
industry (Robert et al., 2015). Furthermore, these reports were all 
limited to single farms/populations, most often due to a single or very 
few horses within the treated groups exhibiting a decrease in fecal egg 
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count reduction, and in none of these studies were horses re-treated to 
confirm the suspicion of ivermectin resistance. Thus, the currently 
available data on ML resistance in cyathostomin populations is scarce 
and mostly inconclusive. Truly convincing evidence with follow-up 
confirmation of full-fledged resistance to ML anthelmintics in cyathos-
tomins has yet to be presented. 
Despite the limited evidence, it is generally believed that ML 
resistance is emerging in cyathostomin populations. This is supported by 
several reports of shortened egg reappearance periods (ERPs) following 
administration of this drug class. Originally, ERPs were reported in the 
9–13 week range for ivermectin (Borgsteede et al., 1993; Boersema 
et al., 1996; Demeulenaere et al., 1997), while moxidectin was capable 
of suppressing strongyle egg shedding for 16–22 weeks (Jacobs et al., 
1995; DiPietro et al., 1997; Demeulenaere et al., 1997). However, in the 
Fig. 1. Flow diagram describing the series of events for the study population consisting of yearlings born in either Kentucky, USA (yellow) or Ireland (green) in 2019. 
The Irish yearlings were imported to the US in October 2019. The flowchart indicates when horses received anthelmintic treatment and what they were treated with. 
The triple anthelmintic treatment administered in April 2020 consisted of moxidectin, oxibendazole, and pyrantel pamoate. (For interpretation of the references to 
colour in this figure legend, the reader is referred to the Web version of this article.) 
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past fifteen years, there have been multiple reports of significantly 
shortened ERPs (von Samson-Himmelstjerna et al., 2007; Relf et al., 
2014; Geurden et al., 2014; Molena et al., 2018) and in some cases as 
short as four weeks for both MLs (Lyons et al., 2008, 2011; Bellaw et al., 
2018). Terminal studies performed at the University of Kentucky have 
demonstrated that for ivermectin, the shortened ERP appears to be due 
to resistance at the luminal L4 stage with efficacy levels often well below 
50% (Lyons et al., 2009; Lyons and Tolliver, 2013). However, with 
moxidectin the pattern is less clear as the efficacy against luminal L4s 
was still above 96% in cyathostomin populations with 4-week ERPs 
(Lyons et al., 2010; Bellaw et al., 2018). Taken together, while the 
multiple reports of shortened ERP may be indicative of emerging resis-
tance, more data are needed to fully understand the possible 
mechanisms. 
In this report, we present a case of unequivocal ML treatment failure 
in a group of Thoroughbred yearlings imported to the US from a farm in 
Ireland. We describe how the lack of efficacy was confirmed through 
rigorous testing, and describe the treatment and management decisions 
made on the farm to mitigate the situation. 
2. Materials and methods 
2.1. Horses 
The data presented herein were obtained from a Thoroughbred 
operation in Central Kentucky. This farm breeds a large number of foals 
every year, but also imports a contingency of weanlings from Europe 
every autumn. Following current recommendations, the farm has 
implemented routine monitoring of parasite egg count levels and 
anthelmintic treatment efficacy. 
The study population consisted of two groups of Thoroughbred 
yearlings born in 2019 and all kept at the same farm in Kentucky, USA. 
One group (25 fillies and 33 colts) were born in Ireland and were im-
ported into the US on October 24, 2019. The other group (26 fillies and 
29 colts) were born on the US farm. The horses were organized in six 
groups (Fig. 1), which were kept separate from each other with no 
overlap in use of paddocks, pastures or barns. As per the usual procedure 
on Kentucky Thoroughbred farms, many of the yearlings were sold in the 
traditional yearling sales in September 2020. Regardless of ownership, 
the horses were then placed into training for the 2021 season. 
2.2. Treatment history 
Prior to weaning, foals at the farm in Ireland were dewormed with 
fenbendazole at 2 and 5 months of age. Post weaning, they were treated 
with ivermectin at 6 months and moxidectin at 7 months of age prior to 
exporting them to the US. The US born population was dewormed with a 
combination of piperazine and fenbendazole at 2 and 4 months of age, 
followed by ivermectin at 5 and 7 months of age. 
2.3. Treatments administered 
The course of events and the timing of anthelmintic treatments are 
outlined in the flow diagram in Fig. 1. All horses were weighed on 
electronic scales on a monthly basis and anthelmintic products were 
administered orally according to weight. 
All horses were administered moxidectin (400 μg/kg, Quest Plus, 
Zoetis, New Jersey, USA) on November 25, 2019, and ivermectin (200 
μg/kg, Equimax, Bimeda, Illinois, USA) was administered to all yearlings 
on February 6, 2020. Given a lack of fecal egg count reduction observed 
among the imported yearlings following these moxidectin and iver-
mectin treatments, Groups 4 and 5 were re-treated 21 days later on 
February 28, 2020 and FEC repeated 14 days following treatment. 
Subsequent to this, the colts in Groups 4 and 5 were allocated randomly 
to two treatment groups; one group was administered moxidectin (400 
μg/kg, Quest, Zoetis, New Jersey, USA) and the other was administered 
a triple combination of oxibendazole (10 mg/kg, Anthelcide, Zoetis, 
New Jersey, USA), pyrantel pamoate (6.6 mg/kg, Strongid P, Zoetis, 
New Jersey, USA), and moxidectin (400 μg/kg, Quest, Zoetis, New 
Jersey, USA). Following this, all yearlings were treated again with 
ivermectin (200 μg/kg, Zimecterin, Boehringer-Ingelheim, Ingelheim, 
Germany) on June 8, 2020 to verify the reduced efficacy observed in 
February. 
2.4. Fecal egg counts 
Fecal samples were collected either rectally or from samples freshly 
deposited on stall floors, were put in airtight containers, kept refriger-
ated, and analyzed within one working week. All post-treatment samples 
were collected at 14 days following anthelmintic administration. 
Strongyle fecal egg counts (FEC) were performed by farm personnel 
using the OvaTector system (BG Medical Products Inc, Venice, Florida, 
USA) with a multiplication factor of 10 eggs per gram (EPG) and sodium 
nitrate (specific gravity 1.25) as flotation medium. 
2.5. Statistical analysis 
Fecal egg count reductions (FECRs) were calculated for each treat-
ment and group using an online web interface providing a Bayesian 
hierarchical model analysis of the data with estimation of mean FECR 
and 95% Credible Interval (Torgerson et al., 2014; Wang et al., 2018). 
Resistance was suspected whenever the group mean FECR fell below 
95% and the lower Credible Interval fell below 90%. 
The FECR data were analyzed using SAS version 9.4 (Cary, NC, USA). 
Data were evaluated for normal distribution with Shapiro-Wilk and 
Kolmogorov-Smirnov statistics as well as normal probability plots, and 
were log-transformed to achieve normal distribution. A mixed linear 
model was constructed for the ivermectin FECR data (treatments A and 
C) with time point and group as class variables. The ‘mixed’ procedure 
was used with repeated measures across the two time points and horse 
ID as random effect. Analyses analyzed for differences between groups 
and time points as well as the effect of the interaction term between 
group and time point. In one set of analyses, the group variable was 
replaced by country of origin (USA or Ireland) to analyze for associated 
trends. Whenever any of the covariates was found significant, a Tukey’s 
pair-wise comparison of the adjusted least squares means was per-
formed. All analyses were interpreted at the α = 0.05 level. 
3. Results 
Results are presented for each of the six groups, three of which were 
US bred and three that were imported from Ireland. 
The three US bred groups (1, 2, 3) were each dewormed with iver-
mectin on two occasions four months apart, and the FECRs were all in 
the 99–100% range (Table 1). The ivermectin FECRs from the imported 
yearlings (groups 4, 5, 6) are reported in Table 2. All three imported 
groups demonstrated reduced ivermectin efficacy. Additionally, group 
6, which was the only group where efficacy was monitored following the 
November 2019 moxidectin treatment, yielded reduced efficacy there as 
well (Table 3). Overall, there were no significant differences in FECR 
between the February and June ivermectin treatments (p = 0.839), but 
there were significant differences between groups (p < 0.001) with 
group 6 demonstrating a significantly lower FECR than groups 1–4. 
There was a significant association between FECR and the interaction 
term between group and time point (p < 0.001) with group 6 having a 
significantly lower FECR than all other groups for the June treatment. 
The analysis with the country of origin variable revealed significantly 
lower FECRs in the Irish yearlings (p < 0.001) but no difference between 
the two treatment time points (p = 0.893). The follow-up treatments 
administered on February 28 in Groups 3 and 4 both demonstrated a 
pronounced lack of reduction, and the June 8 ivermectin treatment 
yielded reduced efficacy in two of the three groups. Table 3 presents the 
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results of treating the imported yearlings with either moxidectin alone 
or the triple combination. Moxidectin efficacy was reduced in all three 
groups, but the triple combination demonstrated a 100% FECR. 
4. Discussion 
The data presented herein are remarkable in at least three ways. 
First, this is the most comprehensive data set demonstrating reduced ML 
efficacy against equine cyathostomins reported to date. Second, reduced 
efficacy was demonstrated to both ivermectin and moxidectin, and the 
suspicion of resistance was confirmed through re-testing. Third, the high 
efficacy of the ivermectin treatments in all three groups of US bred 
horses measured concomitantly with the reduced efficacy in the Irish 
bred horses demonstrates that the drugs were of high quality, adminis-
tered correctly by farm personnel, and that the reduced efficacy was not 
a result of laboratory error. These data present clear evidence that the 
cyathostomin population harbored by the US bred horses were suscep-
tible to ivermectin, whereas the parasites of the Irish imports were 
resistant to both ivermectin and moxidectin. As these populations were 
kept completely separate throughout the study, this is clear evidence 
that the ML resistant parasites were imported from the Irish farm. 
An earlier equine anthelmintic resistance survey indicated that 
anthelmintic resistance levels were more pronounced in Kentucky than 
other southern states, and these levels were among the highest reported 
anywhere in the world (Kaplan et al., 2004). The use of anthelmintics on 
Kentucky Thoroughbred farms is very intense, with the large majority of 
farms deworming their yearlings six times a year or more (Robert et al., 
2015). Thus, it was always the expectation that ML-resistant cyathos-
tomins were very likely to eventually occur in the heart of Thoroughbred 
country in Kentucky. In light of this, it is a genuine surprise that the first 
case of full-fledged ML resistance was diagnosed in horses imported 
from Ireland. A recent survey conducted in Ireland documented that 
parasite control programs adopted by the equine industry there 
(including Thoroughbred farms) were not following current recom-
mendations, with little or no diagnostic monitoring of parasite presence 
and treatment efficacy, and frequent administration of anthelmintic 
treatments with heavy reliance on ML products (Elghryani et al., 2019). 
Thus, several similar risk factors for development of ML resistance were 
also present in Ireland. Nonetheless, it is important to note that the 
Kentucky farm has imported weanlings from Ireland every year for the 
past several years, and that routine testing in previous years had always 
demonstrated full ML efficacy. Furthermore, the anthelmintic treatment 
regimen practiced on the Ireland facility with two benzimidazole 
treatments targeting ascarid parasites followed by two ML treatments 
directed at the strongyle parasites is in line with general recommenda-
tions, and cannot be considered overly excessive compared with general 
trends within the Thoroughbred industry. Thus, it is not possible to 
identify what set of conditions and circumstances led this particular 
cyathostomin population to become resistant, or why it occurred now. 
The heavy reliance on ML anthelmintics for equine strongyle control 
is obviously problematic, but the industry is left with little choice. In 
cyathostomins, anthelmintic resistance is widespread to both the benz-
imidazoles and pyrimidines (Peregrine et al., 2014), often leaving the 
MLs as the only viable treatment option. This is reflected by current 
guidelines for equine parasite control, wherein it is recommended to 
primarily use MLs for strongyle control and only use other drug classes if 
pertinent testing has demonstrated good efficacy (Nielsen et al., 2019; 
ESCCAP 2019; Rendle et al., 2019). While ML resistance has been 
remarkably slow to progress in cyathostomins, the data presented herein 
clearly demonstrate that a resistance break-through can happen, and 
likely is occurring elsewhere as well. It is noteworthy that the degree of 
parasite egg count monitoring adopted by this farm is well above in-
dustry norms. As is most common with cyathostomin infections, the 
horses infected with the ML-resistant parasites were all clinically 
normal; consequently, the ML resistance was discovered here only due 
to this monitoring program. Other equine operations in the US, Ireland, 
Table 1 
Strongyle fecal egg counts presented in eggs per gram of feces (EPG) in three 
groups of US-bred Thoroughbred yearlings and the percent reduction with 95% 
credible intervals (CI) following oral administration of ivermectin (200 μg/kg) 
on two separate occasions.a  
Datea N Pre-treatment (EPG) Post-treatment (EPG) FECR (95% CI) 
Mean Range Mean Range 
Group 1 
A 12 1142.5 530–2070 0 - 100% (99.8–100) 
C 16 868.2 310–1910 0 - 100% (99.7–100) 
Group 2 
A 10 1347.0 720–2640 0 - 100% (99.8–100) 
C 12 1116.7 320–1840 10.8 0–60 99.4% (97.6–100) 
Group 3 
A 24 1236.0 610–1720 0.5 0–60 100% (99.8–100) 
C 26 1239.2 170–2090 0 - 100% (99.9–100)  
a Ivermectin treatments administered on A: February 6 and C: June 8, 2020. 
Table 2 
Strongyle fecal egg counts presented in eggs per gram of feces (EPG) and percent 
reduction with 95% credible intervals (CI) in three groups of yearling Thor-
oughbreds imported from Ireland following oral ivermectin administration (200 
μg/kg) on three separate occasions.a  
Datea N Pre-treatment (EPG) Post-treatment 
(EPG) 
FECR (95% CI) 
Mean Range Mean Range 
Group 4 
A 10 1317.0 620–1970 105.0 0–320 93.5% (85.6–97.6) 
B 8 131.3 10–320 118.9 0–350 33.8% (13.4–61.9) 
C 15 1605.3 10–2680 4.0 0–20 99.8% (99.4–99.9) 
Group 5 
A 16 968.1 550–1720 348.8 20–1170 70.5% (55.5–88.9) 
B 16 348.8 20–1170 358.1 20–760 23.5% (12.6–45.0) 
C 18 1278.9 210–2460 174.1 0–670 87.7% (79.6–93.1) 
Group 6 
A 19 1080.0 510–1980 332.6 20–880 74.5% (62.4–83.2) 
C 25 1246.3 470–2490 570.0 10–1490 62.0% (48.3–72.4)  
a Ivermectin treatments administered on A: February 6, B: February 28, and C: 
June 8, 2020. 
Table 3 
Strongyle fecal egg counts and percent reduction with 95% credible intervals 
(CI) in three groups of yearling Thoroughbreds imported from Ireland following 
either an oral administration of a triple combination (T) consisting of moxidectin 
(400 μg/kg), pyrantel pamoate (6.6 mg/kg) and oxibendazole (10 mg/kg) or a 
single dose of moxidectin (M, 400 μg/kg).   
N Pre-treatment EPG Post-treatment EPG FECR (95% CI) 
Mean Range Mean Range 
Group 4 
Ta 2 336.0 320–350 0 - 100% (76.2–100) 
Ma 5 80.0 10–160 5.0 0–20 90.2% (62.6–98.2) 
Group 5 
Ta 9 313.3 20–760 0 - 100% (98.6–100) 
Ma 7 385.7 180–720 250.0 20–760 57.3% (26.1–78.6) 
Group 6 
Mb 16 1229.4 570–2060 638.8 180–1180 50.0% (30.7–64.2)  
a Treatments administered on April 10, 2020. 
b Treatment administered on November 25, 2019. 
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and elsewhere, most likely already have ML resistant cyathostomins 
without being aware due to a lack of testing and the relatively low 
pathogenicity of cyathostomins. This case clearly illustrates the impor-
tance of quality routine FECR testing, which immediately informed the 
farm manager of the situation and allowed him to react in time by 
keeping the populations completely separate, thereby avoiding an 
introduction of the resistant parasites to the entire facility. 
The triple combination of oxibendazole, pyrantel pamoate and 
moxidectin was administered in an attempt to achieve the desired 100% 
reduction in FEC. We expected that the moxidectin efficacy would be 
somewhat higher than that for ivermectin, given the higher dose and 
lipophilic properties of this molecule. However, this was not observed, 
as the 95% CI for FECR overlapped for both drugs. Although the effi-
cacies of oxibendazole and pyrantel pamoate were not tested separately 
in these horses, the 100% reduction in FEC of the combination suggests 
that one or both of these drugs were reasonably or highly effective. 
However, high efficacy for these two drugs is unlikely on Kentucky 
Thoroughbred farms, as resistance to benzimidazoles and pyrimidines is 
highly prevalent (Kaplan et al., 2004). Consequently, using the triple 
combination to treat ML resistant cyathostomins in Kentucky is unlikely 
to be a sustainable treatment choice over time. We recently demon-
strated that use of a combination of oxibendazole and pyrantel pamoate 
against a cyathostomin population with documented resistance to both 
classes was not efficacious (Scare et al., 2018). Thus, if a triple combi-
nation treatment is used, the efficacy will need to be closely monitored; 
once this approach loses efficacy we will have run out of treatment 
options. The pharmaceutical industry has not introduced any new 
anthelmintic classes with new modes of action for equine usage since 
ivermectin almost 40 years ago, and there are no indications that any 
new anthelmintic classes will be introduced for horses in the foreseeable 
future. The data presented herein strongly demonstrate that the port-
folio of equine anthelmintics is woefully unsatisfactory, leaving 
end-users with few viable treatment options and almost no alternatives, 
when current options fail. 
Some of these imported yearlings were sold at the 2020 September 
yearling sales, while the majority were retained by the owner and sent 
away for training. Thus, they likely brought their ML resistant cya-
thostomins with them and would almost certainly be introducing these 
to the new facilities. With a high degree of national and international 
movement of horses and the general lack of quarantine testing, this 
population of ML resistant worms will quickly spread to numerous lo-
cations, and given the heavy reliance on ML anthelmintics across the 
world, resistant populations will be quickly selected for. While this 
outlook is scary, the fact that these yearlings are destined for a career as 
race horses should mitigate the risk of spread, since they will go into 
training and have little or no access to pasture for the next couple years. 
Exceptions will be injured horses sent home for rehabilitation, situations 
where horses are given a break from training to allow additional 
maturation and growth, or horses that are retired from racing to become 
off-the-track-Thoroughbreds in search of new careers as riding horses. 
Thus, in a many of these horses, the cyathostomin infection may be 
somewhat self-limiting. However, it should be kept in mind that 
encysted cyathostomin larvae undergo arrested development at the 
early third stage, which means that it can take several years for the 
infection to be eliminated, even if effective adulticidal anthelmintics are 
administered (Smith, 1976a, 1976b). Taken together, these yearlings are 
likely to introduce ML resistant cyathostomins to their new facilities, 
and despite the reduced levels of parasite transmission that are typical of 
the management used for Thoroughbred horses in training, spread of 
infection to other horses and properties is likely. Thus, it would be 
pertinent to recommend quarantine testing of ML efficacy for any 
yearlings newly acquired at a sale. 
In conclusion, this study is the first in the world to confirm ML 
resistance in a population of equine cyathostomins through a series of 
repeated testing. We have presented data from a large study population 
(58 and 55 horses in each group), and followed this population over an 
eight-month period, conducting 19 different FECRTs for evaluation of 
ivermectin, moxidectin, and the triple combination of oxibendazole, 
pyrantel pamoate, and moxidectin. Furthermore, the study demon-
strated that the isolate was imported to the US from Ireland, demon-
strating how resistant parasites can quickly traverse continents and 
quickly be spread globally. Equine operations are strongly encouraged 
to heed this threat to equine health, and routinely monitor anthelmintic 
efficacy on a yearly basis. Only by taking such actions will it be possible 
to detect cases like these as early as possible and institute appropriate 
interventions. 
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